The FDA has lifted the clinical hold on Aardvark Therapeutics' investigational drug ARD-101, designed to treat hyperphagia in Prader-Willi Syndrome (PWS), allowing clinical trials to resume. The hold was placed after ECG changes were observed in a separate study, but further testing showed no cardiac events at therapeutic doses. Aardvark plans to continue development following further FDA discussions and will host a webcast to discuss data from the terminated Phase 3 HERO and OLE trials. This development is significant as ARD-101 targets a critical unmet need in PWS, a rare genetic disorder causing insatiable hunger.
The news about Aardvark Therapeutics and its ARD-101 drug for Prader-Willi Syndrome is provided here with a snapshot of the Health sector on Pluang. For readers following Health stocks, as of Oct 23, 2026 02:41 WIB, out of 150 priced US Health-sector stocks, 77 rose and 71 fell. Notable movers include SLS at USD 11.21 with a 1-day change of -7.66% and a typical hold time of 4 days, ABCL at USD 11.34 down 7.35% but with Pluang order activity showing 0% Sell and 100% Buy and a typical hold time of 41 days, and MRVI at USD 7.08 down 6.47% with 0% Sell and 100% Buy order activity and a typical hold time of 4 days.
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Randstad reported revenue and earnings that exceeded expectations, driven by improving business trends and key labor markets. This positive performance signals momentum in the employment services sector. RBC Capital maintained a 'Sector Perform' rati...
MSC Industrial Supply reported strong Q4 results with revenue rising 10.3% year-over-year to about $1.08 billion, surpassing estimates. Adjusted earnings per share increased to $1.45 from $1.09, also beating expectations. Full-year sales grew 6.4% to...
